TY - JOUR
T1 - Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras
T2 - a real-world multicenter observational analysis. The RETROHER study
AU - Vici, Patrizia
AU - Pizzuti, Laura
AU - Natoli, Clara
AU - Moscetti, Luca
AU - Mentuccia, Lucia
AU - Vaccaro, Angela
AU - Sergi, Domenico
AU - Di Lauro, Luigi
AU - Trenta, Patrizia
AU - Seminara, Patrizia
AU - Santini, Daniele
AU - Iezzi, Laura
AU - Tinari, Nicola
AU - Bertolini, Ilaria
AU - Sini, Valentina
AU - Mottolese, Marcella
AU - Giannarelli, Diana
AU - Giotta, Francesco
AU - Maugeri-Saccà, Marcello
AU - Barba, Maddalena
AU - Marchetti, Paolo
AU - Michelotti, Andrea
AU - Sperduti, Isabella
AU - Gamucci, Teresa
PY - 2014/9/24
Y1 - 2014/9/24
N2 - Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted in selected patient populations, we performed a retrospective analysis of HER2-positive early breast cancer patients treated in the “pre-trastuzumab” and “trastuzumab” eras, with the aim to determine patients' outcomes in real-world practice. 925 consecutive HER2-positive breast cancer patients treated with adjuvant chemotherapy in ten Italian oncologic centers were identified. Patients who had received adjuvant chemotherapy alone (cohort A, 352 patients), and patients who had received adjuvant chemotherapy followed or combined with trastuzumab (cohort B, 573 patients) were analyzed. Relapse rate at 3 years, relapse-free survival, and overall survival were significantly more unfavorable in the cohort A than in the cohort B (p
AB - Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted in selected patient populations, we performed a retrospective analysis of HER2-positive early breast cancer patients treated in the “pre-trastuzumab” and “trastuzumab” eras, with the aim to determine patients' outcomes in real-world practice. 925 consecutive HER2-positive breast cancer patients treated with adjuvant chemotherapy in ten Italian oncologic centers were identified. Patients who had received adjuvant chemotherapy alone (cohort A, 352 patients), and patients who had received adjuvant chemotherapy followed or combined with trastuzumab (cohort B, 573 patients) were analyzed. Relapse rate at 3 years, relapse-free survival, and overall survival were significantly more unfavorable in the cohort A than in the cohort B (p
KW - Adjuvant chemotherapy
KW - Breast cancer
KW - HER2-positive
KW - Trastuzumab
KW - Triple positive tumors
UR - http://www.scopus.com/inward/record.url?scp=84918814028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84918814028&partnerID=8YFLogxK
U2 - 10.1007/s10549-014-3133-1
DO - 10.1007/s10549-014-3133-1
M3 - Article
C2 - 25234842
AN - SCOPUS:84918814028
VL - 147
SP - 599
EP - 607
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 3
ER -